These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31722893)

  • 41. Dehydroepiandrosterone in fibrotic interstitial lung disease: a translational study.
    Guler SA; Machahua C; Geiser TK; Kocher G; Marti TM; Tan B; Trappetti V; Ryerson CJ; Funke-Chambour M
    Respir Res; 2022 Jun; 23(1):149. PubMed ID: 35676709
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PET/CT with 18F-FDG- and 18F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis.
    Bondue B; Sherer F; Van Simaeys G; Doumont G; Egrise D; Yakoub Y; Huaux F; Parmentier M; Rorive S; Sauvage S; Lacroix S; Vosters O; De Vuyst P; Goldman S
    J Nucl Med; 2015 Jan; 56(1):127-32. PubMed ID: 25537989
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.
    Behr J; Prasse A; Wirtz H; Koschel D; Pittrow D; Held M; Klotsche J; Andreas S; Claussen M; Grohé C; Wilkens H; Hagmeyer L; Skowasch D; Meyer JF; Kirschner J; Gläser S; Kahn N; Welte T; Neurohr C; Schwaiblmair M; Bahmer T; Oqueka T; Frankenberger M; Kreuter M
    Eur Respir J; 2020 Aug; 56(2):. PubMed ID: 32381492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aerosolized Liposomal Formulation Prevents Enhanced Drug Transfer from Fibrotic Lungs to the Systemic Circulation.
    Togami K; Kurasho K; Kanehira Y; Tada H; Chono S
    Curr Drug Deliv; 2021; 18(7):947-954. PubMed ID: 33372874
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The antifibrotic effects of alveolar macrophages 5-HT2C receptors blockade on bleomycin-induced pulmonary fibrosis in rats.
    Elaidy SM; Essawy SS
    Pharmacol Rep; 2016 Dec; 68(6):1244-1253. PubMed ID: 27686964
    [TBL] [Abstract][Full Text] [Related]  

  • 46. "Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry." Helen E. Jo, Ian Glaspole, Christopher Grainge, Nicole Goh, Peter M.A. Hopkins, Yuben Moodley, Paul N. Reynolds, Sally Chapman, E. Haydn Walters, Christopher Zappala, Heather Allan, Gregory J. Keir, Andrew Hayen, Wendy A. Cooper, Annabelle M. Mahar, Samantha Ellis, Sacha Macansh and Tamera J. Corte.
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28356377
    [No Abstract]   [Full Text] [Related]  

  • 47. "Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension." Irene M. Lang and Sean P. Gaine. Eur Respir Rev 2015; 24: 630-641.
    Eur Respir Rev; 2016 Mar; 25(139):99. PubMed ID: 26929428
    [No Abstract]   [Full Text] [Related]  

  • 48. "Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension." Irene M. Lang, Sean P. Gaine. Eur Respir Rev 2015; 24: 630-641.
    Eur Respir Rev; 2017 Jan; 26(143):. PubMed ID: 28049123
    [No Abstract]   [Full Text] [Related]  

  • 49. "Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice." Stephen Y. Chan and Lewis J. Rubin.
    Eur Respir Rev; 2018 Mar; 27(147):. PubMed ID: 29367412
    [No Abstract]   [Full Text] [Related]  

  • 50. Epithelial Alarmins in Serum and Exhaled Breath in Patients with Idiopathic Pulmonary Fibrosis: A Prospective One-Year Follow-Up Cohort Study.
    Majewski S; Szewczyk K; Białas AJ; Miłkowska-Dymanowska J; Górski P; Piotrowski WJ
    J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31581688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis.
    Chen W; Zhang J; Zhong W; Liu Y; Lu Y; Zeng Z; Huang H; Wan X; Meng X; Zou F; Cai S; Dong H
    Front Pharmacol; 2021; 12():744826. PubMed ID: 34603058
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience.
    Kawamura K; Ichikado K; Ichiyasu H; Anan K; Yasuda Y; Suga M; Sakagami T
    BMC Pulm Med; 2019 Jun; 19(1):113. PubMed ID: 31238929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
    Petnak T; Lertjitbanjong P; Thongprayoon C; Moua T
    Chest; 2021 Nov; 160(5):1751-1763. PubMed ID: 34217681
    [TBL] [Abstract][Full Text] [Related]  

  • 54. "Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension." Irene Lang, Bernhard C. Meyer, Takeshi Ogo, Hiromi Matsubara, Marcin Kurzyna, Hossein-Ardeschir Ghofrani, Eckhard Mayer and Philippe Brenot.
    Eur Respir Rev; 2017 Jun; 26(144):. PubMed ID: 28615306
    [No Abstract]   [Full Text] [Related]  

  • 55. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis.
    Skurikhin E; Nebolsin V; Widera D; Ermakova N; Pershina O; Pakhomova A; Krupin V; Pan E; Zhukova M; Novikov F; Sandrikina L; Morozov S; Kubatiev A; Dygai A
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171668
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
    Maher TM; Strek ME
    Respir Res; 2019 Sep; 20(1):205. PubMed ID: 31492155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series.
    Delanote I; Wuyts WA; Yserbyt J; Verbeken EK; Verleden GM; Vos R
    BMC Pulm Med; 2016 Nov; 16(1):156. PubMed ID: 27863518
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expectations about treatment of idiopathic pulmonary fibrosis: Comparative survey of patients, carers and physicians (the RESPIR French survey).
    Cottin V; Bergot E; Bourdin A; Nunes H; Prévot G; Wallaert B; Marchand-Adam S
    Respir Med Res; 2021 May; 79():100811. PubMed ID: 33618076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.
    Murray LA; Zhang H; Oak SR; Coelho AL; Herath A; Flaherty KR; Lee J; Bell M; Knight DA; Martinez FJ; Sleeman MA; Herzog EL; Hogaboam CM
    Am J Respir Cell Mol Biol; 2014 May; 50(5):985-94. PubMed ID: 24325475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.